Clinton, CT, United States of America

Neil Demers

This inventor holds 1 USPTO granted patent. Top assignee: Pfizer Corporation. Active years: 1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Neil Demers. Retrieved from https://idiyas.com/inventor/neil-demers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Neil Demers: Innovator in Antiparasitic Solutions

Introduction

Neil Demers is a skilled inventor based in Clinton, Connecticut. He has made significant contributions to the field of pharmaceuticals, particularly in developing solutions for parasitic infections. With a keen focus on innovation, Demers has secured a patent that showcases his expertise and dedication to improving health outcomes.

Latest Patents

Demers holds a patent for a process and antiparasitic intermediates for doramectin. This invention is critical in advancing treatment options against various parasitic diseases, thereby enhancing the effectiveness of therapeutics available in the market.

Career Highlights

Throughout his career at Pfizer Corporation, Demers has demonstrated exceptional prowess in pharmaceutical research and development. His contributions have played a pivotal role in the company's commitment to delivering innovative health solutions to patients worldwide.

Collaborations

Neil Demers has collaborated with esteemed colleagues, including Constantine Sklavounos and Thomas C Crawford. Their collective efforts in research and development have magnified the impact of their work, driving forward the quest for effective antiparasitic treatments.

Conclusion

In summary, Neil Demers is a notable inventor whose work has implications for global health through innovative antiparasitic solutions. His achievements at Pfizer Corporation and collaborations with other professionals illustrate his importance to the field of pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…